Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD
Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).
2 findings from 1 review
Incidence of CNV at 24 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 24 months compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of CNV at 36 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 36 months compared with placebo (moderate certainty).
1 finding from 1 review
Progression of AMD (dichotomous) · people with AMD
Omega 3 fatty acids showed no clear difference in progression of AMD over 5 years compared with placebo (high certainty).
1 finding from 1 review
Adverse effects · people with AMD
Omega 3 fatty acids leads to higher adverse effects compared with placebo (high certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in change in tear film stability, measured using tear break‐up time… compared with placebo (moderate certainty).
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tear film stability · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at 1‐month · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with oral omega‐6 PUFAs (moderate certainty).
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in ocular surface staining at 1‐month compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review